Legal. Legal framework: Yes. Authorizing legislation: Ley N° Ley de Los Productos Farmaceuticos, Dispositivos Médicos y Productos Sanitarios (Nov. Relevant documents: Ley Nº ‑ Ley de los Productos Farmacéuticos, Dispositivos Médicos y Productos Sanitarios (Law No. on Pharmaceutical . Ley N° Ley de los Productos Farmacéuticos, Dispositivos Médicos y Productos Sanitarios (Law No. on pharmaceutical products.
|Published (Last):||19 June 2014|
|PDF File Size:||9.87 Mb|
|ePub File Size:||9.3 Mb|
|Price:||Free* [*Free Regsitration Required]|
The proportions of brand anti-infectives new registrations were greater than the ones for generics throughout the study period, and this difference was even greater from to It is important that prescribers and patients understand these changes and increase their trust on generics.
Table 6 Characteristics of the 57 unique anti-infectives with statuses 4 to 8. Coronado J, Espinoza J. Rapid evaluation -with indicators- of the national pharmaceutical situation.
On the other hand, two studies assessed the US-Jordan FTA and both concluded that the new data exclusivity regulation delayed generic entry and increased expenditures for medicines without generic competition [ 2324 ]. The Law stipulates the time allowed to review applications and grant marketing approvals according to the new categories of medicines:.
ley no 29459 pdf
The majority were the combination of sulfonamides and trimethoprim followed by penicillin with extended spectrum and penicillin with beta-lactamase inhibitors as well as fluoroquinolones. Anti-infectives awaiting registration can be anti-infectives that have not submitted GMP certificates, have failed plant inspections, or have not yet presented pre-clinical or clinical studies to prove safety and efficacy.
Conclusions The new NDP reduced the number of brand and generic registrations; generics had the largest decline in registrations.
Furthermore, this table shows 2945 ATC classification for anti-infectives with statuses 4 to 8 found in the retail pharmacies. Updated table Oct This is confirmed by the results obtained from on 10 retail pharmacies in which almost the double of brand and generic anti-infectives were of Peruvian origin. For the case study, data were collected from 10 retail pharmacies located in different socio-economic strata in the southern city of Arequipa, the second most industrialized and commercial city of Peru.
The number of anti-infectives that were re-registered declined from in to 11 in These pharmacies carried Human resources in health by This drop is related to the longer time required for registration, the bioavailability and bioequivalence requirements, the GMP certificate requirement, and the first lot quality control defined by the NDP after the signing of the FTA. The awaiting registrations started with 48 inincreasing to in The public health sector is financed by subsidies indirect contributions and by social security direct contributions.
Proceedings of the Global Forum on Competition. FTAs may provide opportunities for changes in regulatory systems and improving the safety, efficacy and quality of medicines. Regulation of the registration, control and vigilance of pharmaceutical products, medical devices and sanitary products. Data from the 10 retail pharmacies were matched with the anti-infectives DIGEMID database from January to Augustto record the registration history of each anti-infective.
Free Trade Agreements FTA are controversial for threatening important aspects of health especially access to affordable medicines. The anti-infectives mostly found were penicillins with extended spectrum, macrolides, cephalosporins, fluoroquinolones and combination of sulfonamides and trimethoprim the government covers the treatments for HIV and tuberculosis in the public sector; this is why the majority of anti-infectives in the retail pharmacies were antibiotics.
Pharmacies in the low socio-economic area of the city had the highest proportion of generics Law 29, also includes chapters regarding universal access and rational use of medicines, promotion and research [ 14 ].
The General Health Law approved a simple procedure for the registration application process of pharmaceuticals that included an affidavit ensuring quality, safety and efficacy; analysis protocol from another country; and a free sale certificate.
The authors thank Dr. Lopert R, Gleeson D.
New medicines-new molecular entities with license and data protection u other safety and efficacy data not disclosed. The IP chapter includes, among others, stronger protections for patents and test data as well as tough penalties for piracy and counterfeiting. Table 3 Number and proportion of new registrations of brand and generic anti-infectives from January to April The metropolitan area of the province of Arequipa has pharmacies and drugstores located among its 18 districts.
The private health care system is mainly represented by clinics and other private entities like companies providing health insurance plans.
The changes in the Peruvian drug leey, as a consequence of the US-Peru FTA, have created uncertainty about their implications in the short and long term. This cost did not include the opportunity cost of the time elapsed between the initiation of the procedure to obtain the marketing approval and the effective granting of the license.
The objectives of Law were to adapt the national drug regulation to the requirements of the FTA, to implement new drug registration requirements, and to reach the objectives of the NDP of universal access and rational use of medicines.
Whereas, the constitution protects free market competition and bans price control measures in bo private sector.
ley no pdf – PDF Files
This study is intended to answer some of the research questions that arise as a result of the signing of the trade agreement and the subsequent implementation of the NDP. Regulatory changes may occur without external changes, however, it may be difficult to reach a consensus with the pharmaceutical market stakeholders. The military and police have their own health system and infrastructure.
Reducing the barriers to market competition, including IP regulation, should leu one of the goals of the NDP. That, leyy is necessary to modify the system of registration of pharmaceutical products so that the health authority can demand certain information relevant to the evaluation and determination of the safety and efficacy of said products …….